Oxford Immunotec Global PLC Income Statement 2020-2011 | OXFD

Brief overview of income trends at Oxford Immunotec Global PLC

The conclusions below are based on five years of reported results. Revenue reported by Oxford Immunotec Global PLC was 49.5 million dollars at the beginning of the period and 73.7 million dollars at the end. The total change was +48.9%, with a CAGR of approximately 8.3%. Sales increased steadily, although without strong acceleration.

At the gross-profit level, the result moved from 25.5 million dollars to 54.4 million dollars, a change of +113.5%. Gross margin moved from 51.5% to 73.8%. The business retained more gross profit from each unit of revenue.

EBITDA was −$20.1 million at the beginning and −$3.3 million at the end of the period (+83.8%). EBITDA expanded faster than the top line. Comparing the endpoints gives EBITDA margins of −40.6% and −4.4%. The business generated more EBITDA from each unit of revenue.

Across the five years, the net result shifted from −22.2 million dollars to −1.8 million dollars. The loss reduction is constructive, but the recovery is incomplete.

Market capitalization changed from 204 million dollars to 421 million dollars (+106.6%). Higher capitalization indicates improving investor confidence.

Conclusion

The figures do not all move in the same direction. Key strengths include a stronger final result, revenue expansion and positive operating leverage. The most visible risks are a narrow EBITDA buffer. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.